Chenxin Zhou

Chenxin Zhou

Auto-generated profile, based on publicly available information

Chenxin Zhou

Beijing Children’s Hospital, Capital Medical University , National Center for Children’s Health, Beijing

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2025 in British Journal of Haematology
Verified
Journal Article
Closed access
WWWenqian Wang
Wenqian Wang
YZYunZe Zhao
YunZe Zhao
JGJian Ge
Jian Ge
ZFZishi Fang
Zishi Fang
CZChenxin Zhou
Chenxin Zhou
RZRui Zhang
Rui Zhang

29 April 2026 in The Oncologist
Verified
Journal Article
Open access
CZChenxin Zhou
Chenxin Zhou
HYHaixia Yang
Haixia Yang
SLShilin Liu
Shilin Liu
WSWenyuan Shi
Wenyuan Shi
BSBaosheng Sun
Baosheng Sun
RZRui Zhang
Rui Zhang
Background: Langerhans cell histiocytosis (LCH) is a rare inflammatory neoplasm most commonly involving bone. However, data on single-system, single-site LCH (SS-s-LCH), particularly with unifocal bone disease, remain limited. Management strategies for unifocal osseous LCH vary globally, and the safety of a watchful-waiting approach is not well-defined. This study aimed to evaluate whether patients with osseous SS-s-LCH can be managed with observation alone without compromising long-term outcomes. Methods: In this retrospective, multicenter study, we enrolled children with biopsy-proven osseous SS-s-LCH from seven centers in the Chinese Children’s Histiocytosis Group, excluding those with central nervous system (CNS)-risk bone lesions. The primary endpoint was 3-year event-free survival (EFS). Events were defined as disease progression or relapse. Results: The cohort included 134 patients with a median follow-up of 36.0 months. Involved sites were cranial bones (n = 37), vertebrae (n = 33), and other bones (n = 64). At final follow-up, 16 patients had experienced an event, yielding a 3-year EFS of 88.1% (95% CI: 81.5–92.5%). Events included new lesions (n = 14) and primary lesion expansion (n = 2), with 93.8% (15/16) occurring within the first 12 months after diagnosis. EFS did not differ significantly by involved site or mutation status. However, patients staged by PET-CT at diagnosis had a significantly higher 3-year EFS (97.6%) than those staged by conventional imaging (83.7%) (p < 0.05). Long-term quality of life was satisfactory in all assessed patients. Conclusion: Watchful waiting is a safe and effective management strategy for children with unifocal osseous SS-s-LCH. Initial staging with PET-CT may be associated with superior event-free survival, highlighting its potential value in refining risk assessment.